2023-07-11 07:52:18 ET
- Silence Therapeutics ( NASDAQ: SLN ) to receive a $4M cash payment from Hansoh Pharmaceutical Group Company following the achievement of two undisclosed preclinical milestones. M payment is the second and third research milestone payments achieved under the collaboration, with first milestone payment of $2M received in April 2022.
- This payment follows $10M payment in AstraZeneca collaboration in May and reflects our ongoing efforts to advance our partnered pipeline.
- Silence and Hansoh entered a collaboration in October 2021 to develop siRNAs (“short interfering RNAs”) leveraging Silence’s proprietary mRNAi GOLD platform for three undisclosed targets.
- Hansoh has made a total of $16M upfront payment to Silence and can receive up to $1.3B in development, regulatory and commercial milestones. Silence is also eligible to receive royalties tiered from low double-digit to mid-teens on Hansoh net product sales.
- Source: Press Release
For further details see:
Silence therapeutics to receive another $4M payment from Hansoh Pharma collaboration